Sobi buying Novimmune assets as it refocuses R&D

Less than a year after gaining an exclusive worldwide license for Gamifant emapalumab from Novimmune, Sobi is acquiring a newco formed around the hematology therapy for CHF515 million ($519.2 million) and

Read the full 312 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE